Thyrotoxicosis with pegylated interferon alfa-2b.
BACKGROUND: Despite adequate surgery, a diagnosis of stage III melanoma carries a high risk of relapse, and hence mortality. Interferon alfa is the only treatment that has currently been shown to alter the natural history of the disease, delaying relapse-free survival, particularly in patients with...
| Hauptverfasser: | , , |
|---|---|
| Format: | Journal article |
| Sprache: | English |
| Veröffentlicht: |
2010
|